Finland - finsk - Fimea (Suomen lääkevirasto)

mcneil, a division of janssen- cilag oy - nicotini bitartras dihydricus - resoribletti - 2 mg - nikotiini

Finland - finsk - Fimea (Suomen lääkevirasto)

mcneil, a division of janssen- cilag oy - nicotini bitartras dihydricus - resoribletti - 4 mg - nikotiini

Finland - finsk - Fimea (Suomen lääkevirasto)

mcneil, a division of janssen- cilag oy - nicotini bitartras dihydricus - imeskelytabletti - 2 mg - nikotiini

Finland - finsk - Fimea (Suomen lääkevirasto)

glaxosmithkline consumer healthcare a/s - nicotini bitartras dihydricus - imeskelytabletti - 1 mg - nikotiini

Finland - finsk - Fimea (Suomen lääkevirasto)

glaxosmithkline consumer healthcare a/s - nicotini bitartras dihydricus - imeskelytabletti - 2 mg - nikotiini

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - nicotinic acid, quantity: 250 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; povidone; purified talc - nicotinic acid is an essential dietary constituent, the lack of which leads to the clinical condition known as pellagra, which is characterised by loss of appetite, lethargy, weakness, diarrhoea, dermatitis and mental changes. an erythematous eruption resembling sunburn first appears on the back of the hands. other areas exposed to light are later involved and eventually the lesions may be more widespread. the cutaneous manifestations are characteristically symmetrical and may darken, desquamate and scar. nicotinic acid has been approved for the treatment of hypercholesterolaemia and hypertriglyceridaemia. it should be used as adjunctive therapy in addition to diet and other measures. nicotinic acid can also be used to treat frederickson-lees levy hyperlipoproteinaemia type ii, iib, iii, iv and v.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - nicotinic acid 100mg equivalent to nicotinic aciid premix base 105 mg - tablet - 100 mg - active: nicotinic acid 100mg equivalent to nicotinic aciid premix base 105 mg excipient: hydrated silica lactose monohydrate magnesium stearate

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - nicotinic acid 25mg equivalent to nicotinic acid premix base 26.25 mg - tablet - 25 mg - active: nicotinic acid 25mg equivalent to nicotinic acid premix base 26.25 mg excipient: hydrated silica lactose monohydrate magnesium stearate

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - nicotinic acid 504.79mg - tablet - 500 mg - active: nicotinic acid 504.79mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol lactose monohydrate magnesium stearate povidone

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - nicotinic acid 50.48mg - tablet - 50 mg - active: nicotinic acid 50.48mg excipient: colloidal silicon dioxide ethanol lactose monohydrate magnesium stearate povidone